Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients

Therapeutic Drug Monitoring

Volumn 30, Issue 1, 2008, Pages 41-45

  Hermida, Jesús ^a   Paz, Eduardo ^b   Tutor, J Carlos ^a,b  

^a Instituto de Salud Carlos III   (Spain)

^b Hôpital Psychiatrique de Conxo   (Spain)

Author keywords

Clozapine; Norclozapine; Serum and plasma; Therapeutic drug monitoring

Indexed keywords

CLOZAPINE; NORCLOZAPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LYMPHOCYTE COUNT; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; SCHIZOPHRENIA; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; HUMANS; PLASMA; SCHIZOPHRENIA; SERUM;

EID: 38549179475     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815f4e72     Document Type: Article

References (24)

1. Schultze PF. What is an adequate trial with clozapine? Therapeutic drug monitoring and the response in treatment: refractory schizophrenia. Clin Pharmacokinet. 2003;42:607-618.
2. Elrich S, Bauman B, Wolf R, et al. Therapeutic drug monitoring of clozapine and relapse: a retrospective study of routine clinical data. Int J Clin Pharmacol Ther. 2003;41:3-13.
3. Bauman P, Hiemke C, Ulrich S, et al. TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
4. Hiemke C, Dragicevic A, Gründer G, et al. Therapeutic drug monitoring of new antipsychotic drugs. Ther Drug Monit. 2004;26:156-160.
5. Zernig G, Ng K, Hiemke C, et al. Therapeutic drug monitoring-based clozapine dosing recommendations. Ther Drug Monit. 2007;29:130-131.
6. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentration: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24:70-78.
7. Oo TZ, Wilson JF, Naidoo D, et al. Therapeutic monitoring of clozapine in Australia: the need for consensus. Ther Drug Monit. 2006;28:696-699.
8. Kaladjian A, Bery B, Deturmeny E, et al. Clozapine monitoring: plasma or serum levels? Ther Drug Monit. 1999:21:327-329.
9. Ulrich S, Wolf R, Staedt J. Serum levels of clozapine and relapse. Ther Drug Monit. 2003;25:252-255.
10. Oyewumi LK, Cernovsky ZZ, Freeman DJ. Autonomic signs and dosing during initial steps of clozapine therapy. Med Sci Monit. 2004;10:P119-P123.
11. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients with therapeutic doses. Psychopharmacology. 2003;170:157-166.
12. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62:1049-1053.
13. Xiang YQ, Zhang ZJ, Weng YZ, et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res. 2006;83:201-210.
14. Flanagan RJ, Yusufi B, Barnes TR. Comparability of whole-blood and plasma clozapine and norclozapine concentrations. Br J Clin Pharmacol. 2003;56:135-138.
15. Eksborg S. Evaluation of method-comparison data. Clin Chem. 1981;27:1311-1312.
16. Knoll E, Hafner F, Dettmer K, et al. The determination of calcium, glucose, urea and uric acid using the Kodak Ektachem multiplayer technology: an evaluation. J Clin Chem Clin Biochem. 1982;20:491-498.
17. Harris EK. Proposed goals for analytical precision and accuracy in single-point diagnostic testing. Theoretical basis and comparison with data from College of American Pathologists proficiency surveys. Arch Pathol Lab Med. 1988;112:416-420.
18. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991;16:249-255.
19. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical methods validation-A revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
20. Schaber G, Stevens I, Gaertner HJ, et al. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 1998;46:453-459.
21. Goossen RB, Freeman DJ, Satchell AM, et al. Monitoring clozapine: are finger prick blood and plasma clozapine levels equivalent to arm venipuncture blood and plasma levels?. Ther Drug Monit. 2003;25:469-472.
22. Gardner I, Leeder JS, Chin T, et al. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol Pharmacol. 1998;53:999-1008.
23. Bransky A, Korin N, Nemirovsky Y, et al. Correlation between erythrocytes deformability and size: A study using a microchannel based cell analyser. Microvasc Res. 2007;73:7-13.
24. Viswanathan CT, Bansal S, Booth B, et al. Workshop/conference report-Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 2007;9:E30-E42.